These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12392802)

  • 21. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of heroin abstinence in opiate substitution therapy in heroin-only users and dual users of heroin and crack.
    Heidebrecht F; MacLeod MB; Dawkins L
    Addict Behav; 2018 Feb; 77():210-216. PubMed ID: 29065377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
    Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
    Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users.
    Gandhi DH; Jaffe JH; McNary S; Kavanagh GJ; Hayes M; Currens M
    Addiction; 2003 Apr; 98(4):453-62. PubMed ID: 12653815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three methods of opioid detoxification in a primary care setting. A randomized trial.
    O'Connor PG; Carroll KM; Shi JM; Schottenfeld RS; Kosten TR; Rounsaville BJ
    Ann Intern Med; 1997 Oct; 127(7):526-30. PubMed ID: 9313020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
    Oreskovich MR; Saxon AJ; Ellis ML; Malte CA; Reoux JP; Knox PC
    Drug Alcohol Depend; 2005 Jan; 77(1):71-9. PubMed ID: 15607843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
    Chawla JM; Pal H; Lal R; Jain R; Schooler N; Balhara YP
    J Opioid Manag; 2013; 9(1):35-41. PubMed ID: 23709302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom-triggered dose titration study.
    Lintzeris N; Bammer G; Rushworth L; Jolley DJ; Whelan G
    Drug Alcohol Depend; 2003 Jun; 70(3):287-94. PubMed ID: 12757966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine dosing regime in the management of out-patient heroin withdrawal.
    Lintzeris N
    Drug Alcohol Rev; 2002 Mar; 21(1):39-45. PubMed ID: 12189003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2000; (3):CD002025. PubMed ID: 10908521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emperor' s new clothes.
    Schnoll SH
    J Addict Dis; 2003; 22(4):1-4. PubMed ID: 14723473
    [No Abstract]   [Full Text] [Related]  

  • 33. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
    Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
    Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P300 assessment of opiate and cocaine users: effects of detoxification and buprenorphine treatment.
    Kouri EM; Lukas SE; Mendelson JH
    Biol Psychiatry; 1996 Oct; 40(7):617-28. PubMed ID: 8886295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation.
    Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
    Psychopharmacology (Berl); 2008 Jun; 198(2):149-58. PubMed ID: 18327673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine.
    Ponizovsky AM; Grinshpoon A; Margolis A; Cohen R; Rosca P
    Addict Behav; 2006 Nov; 31(11):2002-13. PubMed ID: 16524668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An exploratory study of buprenorphine use in Bangladesh: a note.
    Ahmed SK; Ara N
    Subst Use Misuse; 2001 Jun; 36(8):1071-83. PubMed ID: 11504153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic treatment of heroin-dependent patients.
    O'Connor PG; Fiellin DA
    Ann Intern Med; 2000 Jul; 133(1):40-54. PubMed ID: 10877739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.
    White J; Bell J; Saunders JB; Williamson P; Makowska M; Farquharson A; Beebe KL
    Drug Alcohol Depend; 2009 Jul; 103(1-2):37-43. PubMed ID: 19403243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.